Neurocrine Biosciences Inc (NBIX)
117.43
-5.44
(-4.43%)
USD |
NASDAQ |
Nov 15, 16:00
117.22
-0.21
(-0.18%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (Quarterly): 195.00M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 195.00M |
| June 30, 2024 | 191.10M |
| March 31, 2024 | 159.40M |
| December 31, 2023 | 137.50M |
| September 30, 2023 | 142.20M |
| June 30, 2023 | 145.80M |
| March 31, 2023 | 139.50M |
| December 31, 2022 | 118.00M |
| September 30, 2022 | 107.70M |
| June 30, 2022 | 135.90M |
| March 31, 2022 | 102.20M |
| December 31, 2021 | 87.40M |
| September 30, 2021 | 92.70M |
| June 30, 2021 | 74.80M |
| March 31, 2021 | 73.20M |
| December 31, 2020 | 66.70M |
| September 30, 2020 | 69.10M |
| June 30, 2020 | 80.90M |
| March 31, 2020 | 58.30M |
| December 31, 2019 | 55.30M |
| September 30, 2019 | 45.30M |
| June 30, 2019 | 61.70M |
| March 31, 2019 | 37.70M |
| December 31, 2018 | 34.38M |
| September 30, 2018 | 35.48M |
| Date | Value |
|---|---|
| June 30, 2018 | 36.99M |
| March 31, 2018 | 48.95M |
| December 31, 2017 | -4.386M |
| September 30, 2017 | 22.46M |
| June 30, 2017 | 21.87M |
| March 31, 2017 | 51.88M |
| December 31, 2016 | 22.58M |
| September 30, 2016 | 20.94M |
| June 30, 2016 | 26.86M |
| March 31, 2016 | 23.90M |
| December 31, 2015 | 21.81M |
| September 30, 2015 | 24.39M |
| June 30, 2015 | 18.72M |
| March 31, 2015 | 16.58M |
| December 31, 2014 | 15.50M |
| September 30, 2014 | 12.19M |
| June 30, 2014 | 10.16M |
| March 31, 2014 | 8.572M |
| December 31, 2013 | 8.918M |
| September 30, 2013 | 9.49M |
| June 30, 2013 | 10.53M |
| March 31, 2013 | 10.31M |
| December 31, 2012 | 9.097M |
| September 30, 2012 | 9.86M |
| June 30, 2012 | 8.818M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
55.30M
Minimum
Dec 2019
195.00M
Maximum
Sep 2024
111.64M
Average
104.95M
Median
Research and Development Expense (Quarterly) Benchmarks
| Repligen Corp | 10.58M |
| West Pharmaceutical Services Inc | 15.50M |
| Bruker Corp | 98.10M |
| The Cooper Companies Inc | 39.00M |
| Integra Lifesciences Holdings Corp | 27.44M |